Loading stock…

Harmony Biosciences Holdings, Inc. (HRMY) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Harmony Biosciences Holdings, Inc.

HRMYMarket cap $2.29BPrice $39.3

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and sells treatments for rare, underserved sleep disorders like narcolepsy. Its flagship drug Wakix was the first non-scheduled narcolepsy treatment approved by the FDA, carving out a niche big pharma ignored.

In Bastion Portfolios?

52W Return+52%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+26%9

Revenue Forecast

Rev CAGR (1y)+19%8

Rev CAGR (3y)+13%8

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+94%10

EPS Growth Y+2+33%9

EPS Growth Y+3+1%4

Quality

Margins

EBIT Margin24%8

Net Income Margin19%8

Free Cash Flow Margin37%10

Debt

Net Debt/EBITDA-2.010

Efficiency

ROE20%8

ROA15%9

Earnings Stability55

GEAR+VERY STRONG99

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)109

P/E Ratio (Forward 3y)510

P/BV2.36

EV Multiples

EV/EBITDA Fwd510

EV/EBIT Fwd510

Yield

Free Cash Flow Yield15.5%10

Dividend Yieldna–

Momentum

Short term

1 month return-6%4

3 month return+3%7

YTD return+5%6

Mid term

Price vs 52wHigh90%8

1 year return+48%9

Long term

3 year return+21%4

5 year return+9%4

Risk Shield

Price Risk

Beta1.04

Volatility41%4

Free Cash Flow

Free Cash Flow Margin37%10

Free Cash Flow Yield15.5%10

Quality

ROCE22%9

Earnings Stability55

Net Debt/EBITDA-2.010

02Growth

Is it actually growing, and how fast?

HRMYHarmony Biosciences Holdings

Revenue FY25$868M

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+26%9

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+94%10

EPS growth, FY27E+33%9

EPS growth, FY28E+1%4

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 26%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 33%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 26%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return+3%7

YTD return+5%6

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+48%9

3-year return+21%4

5-year return+9%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 48% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+3%).

WATCH

Average long-term results. Multi-year returns are middling (+21% over three years and +8.8% over five), roughly average for the market.

Returns sit at the market level over the past month (-6%) and so far this year (+5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Harmony Biosciences Holdings, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

HRMYHarmony Biosciences Holdings

Revenue FY25$868M

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+26%9

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+94%10

EPS growth, FY27E+33%9

EPS growth, FY28E+1%4

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 26%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 33%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 26%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return+3%7

YTD return+5%6

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+48%9

3-year return+21%4

5-year return+9%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 48% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+3%).

WATCH

Average long-term results. Multi-year returns are middling (+21% over three years and +8.8% over five), roughly average for the market.

Returns sit at the market level over the past month (-6%) and so far this year (+5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Harmony Biosciences Holdings, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community